A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
=== Others === One categorization distinguishes between subjectivist, objectivist, and hybrid theories. Subjectivist theories understand well-being as a purely subjective phenomenon characterized by the individual's own perspective, mental states, and attitudes. Objectivist theories rely only on objective factors in their definition, like health and achievement. Hybrid theories incorporate both subjective and objective components. For example, one version states that well-being consists in the subjective appreciation of objective goods. A further distinction is between monist and pluralist theories. Monist theories hold that a single good is responsible for well-being, meaning that all types of well-being share the same essential features. Pluralist theories see well-being as a diverse phenomenon that manifests in many forms without a single essence characteristic of all of them. For instance, objective list theories are pluralist views, whereas hedonism and desire theories are monist views.
Beta cells in the islets of Langerhans release insulin in two phases. The first-phase release is rapidly triggered in response to increased blood glucose levels, and lasts about 10 minutes. The second phase is a sustained, slow release of newly formed vesicles triggered independently of sugar, peaking in 2 to 3 hours. The two phases of the insulin release suggest that insulin granules are present in diverse stated populations or "pools". During the first phase of insulin exocytosis, most of the granules predispose for exocytosis are released after the calcium internalization. This pool is known as Readily Releasable Pool (RRP). The RRP granules represent 0.3-0.7% of the total insulin-containing granule population, and they are found immediately adjacent to the plasma membrane. During the second phase of exocytosis, insulin granules require mobilization of granules to the plasma membrane and a previous preparation to undergo their release. Thus, the second phase of insulin release is governed by the rate at which granules get ready for release. This pool is known as a Reserve Pool (RP). The RP is released slower than the RRP (RRP: 18 granules/min; RP: 6 granules/min). Reduced first-phase insulin release may be the earliest detectable beta cell defect predicting onset of type 2 diabetes. First-phase release and insulin sensitivity are independent predictors of diabetes. The description of first phase release is as follows:
Injection, also known as "slamming", "banging", "shooting up", "digging" or "mainlining", is a popular method which carries relatively greater risks than other methods of administration. Heroin base (commonly found in Europe), when prepared for injection, will only dissolve in water when mixed with an acid (most commonly citric acid powder or lemon juice) and heated. Heroin in the east-coast United States is most commonly found in the hydrochloride salt form, requiring just water (and no heat) to dissolve. Users tend to initially inject in the easily accessible arm veins, but as these veins collapse over time, users resort to more dangerous areas of the body, such as the femoral vein in the groin. Some medical professionals have expressed concern over this route of administration, as they suspect that it can lead to deep vein thrombosis. Intravenous users can use a variable single dose range using a hypodermic needle. The dose of heroin used for recreational purposes is dependent on the frequency and level of use. As with the injection of any drug, if a group of users share a common needle without sterilization procedures, blood-borne diseases, such as HIV/AIDS or hepatitis, can be transmitted. The use of a common dispenser for water for the use in the preparation of the injection, as well as the sharing of spoons and filters can also cause the spread of blood-borne diseases. Many countries now supply small sterile spoons and filters for single use in order to prevent the spread of disease.
Sources: en.wikipedia.org
Prix Galien CEE Pro Bono Humanum Award: In November 2025, Thomsen accepted the Prix Galien CEE Pro Bono Humanum Award on behalf of the Novo Nordisk Foundation, which received the distinction for its contributions to global health initiatives and scientific research. The award was presented at the Central and Eastern Europe edition of the Prix Galien programme in Warsaw, Poland. PwC Business Executive of the Year 2025: In 2025, Thomsen received PwC Denmark's Business Executive of the Year award. The distinction is presented annually to executives in Danish business who have demonstrated notable leadership, strategic influence, and impact on society. PwC's award committee highlighted Thomsen's role in leading the Novo Nordisk Foundation and its expansion of scientific, global health and sustainability initiatives. Golden Plate Award (2024): Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer. Knight of the Order of the Dannebrog: On December 12, 2022, he was appointed as a Knight of the Order of the Dannebrog by the Danish Royal House
== Publications == Robertson published widely over a range of scientific subjects, including his life-long interest in the biochemical processes underlying higher nervous functions and cognition. In 1932, the Australian biochemist, Mary Campbell Dawbarn, compiled an extensive list of Robertson's publications for The Robertson Memorial Volume. She cited 7 books, 174 articles, and 26 other items, published between 1904 and 1929 of which Robertson was joint author. His publications included an early (1914) work, especially written for children; and, later, three significant textbooks, one of which had two editions:
=== LGBTQ+ rights === At the same time, her federal voting record included support for legislation protecting gender identity and expression under Canadian human rights and criminal law. In 2021, she stated that she opposed coercive conversion therapy. Still, she criticized Bill C-6 because its definition was, in her view, too broad and insufficiently precise. While campaigning for leadership of the Conservative Party of British Columbia, she promised to end provincial sexual orientation and gender identity inclusive (SOGI) education.
== External links == Picot, J; Hartwell, D; Harris, P; Mendes, D; Clegg, A J; Takeda, A (2012). "The effectiveness of interventions to treat severe acute malnutrition in young children: a systematic review". Health Technology Assessment. 16 (19): 1–316. doi:10.3310/hta16190. PMC 4781582. PMID 22480797. NBK98566. Media related to Kwashiorkor at Wikimedia Commons The dictionary definition of kwashiorkor at Wiktionary
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.